New Brunswick, NJ—A 2019 study on Natreon’s product PrimaVie (shilajit) has shown benefits for retention of muscular strength and decreased hydroxyproline, according to a press release.
The 8-week, randomized, placebo-controlled, double-blind, clinical trial on active, healthy, males examined the impact that PrimaVie has on fatigue-induced percent decline in strength and concentric peak torque and hydroxyproline levels. The participants received 500-mg of PrimaVie a day or a 250-mg placebo. According to the release, after the 8-week period, those who took the 500-mg of PrimaVie were resistant to fatigue and had greater muscular strength.
This study is published in the January 2019 Journal of International Society of Sports Nutrition by Dr.’s Keller and Housh, researchers in sports nutrition from the University of Nebraska-Lincoln. This study is the 9th clinical trial on PrimaVie, according to the release.
“We are very excited about these results of from the University of Nebraska-Lincoln (UNL) as this enhances our growing body of research highlighting PrimaVie’s role in collagen support,” said Dr. Sanni Raju, CEO of Natreon. “Our previous clinical studies at Ohio State University, discovered that PrimaVie upregulates collagen and other extra cellular matrix protein genes synergistically with exercise. Furthermore, the UNL study results show PrimaVie supplementation decreases degradation of collagen in the body as evidenced by decreases in hydroxyproline. These are significant findings because it shows that PrimaVie can work two ways to enhance collagen in the body and additionally it upregulates other extra cellular matrix protein genes.”
The release also states that PrimaVie is the only organic, Non-GMO, and GRAS affirmed shilajit extract on the market.